首页> 外文期刊>American Journal of Hematology >The role of carbon monoxide and heme oxygenase in the prevention of sickle cell disease vaso-occlusive crises
【24h】

The role of carbon monoxide and heme oxygenase in the prevention of sickle cell disease vaso-occlusive crises

机译:一氧化碳和血红素氧酶在防止镰状细胞疾病血管闭塞危机中的作用

获取原文
获取原文并翻译 | 示例
       

摘要

Sickle Cell Disease (SCD) is a painful, lifelong hemoglobinopathy inherited as a missense point mutation in the hemoglobin (Hb) beta-globin gene. This disease has significant impact on quality of life and mortality, thus a substantial medical need exists to reduce the vaso-occlusive crises which underlie the pathophysiology of the disease. The concept that a gaseous molecule may exert biological function has been well known for over one hundred years. Carbon monoxide (CO), although studied in SCD for over 50 years, has recently emerged as a powerful cytoprotective biological response modifier capable of regulating a host of physiologic and therapeutic processes that, at low concentrations, exerts key physiological functions in various models of tissue inflammation and injury. CO is physiologically generated by the metabolism of heme by the heme oxygenase enzymes and is measurable in blood. A substantial amount of preclinical and clinical data with CO have been generated, which provide compelling support for CO as a potential therapeutic in a number of pathological conditions. Data underlying the therapeutic mechanisms of CO, including in SCD, have been generated by a plethora of in vitro and preclinical studies including multiple SCD mouse models. These data show CO to have key signaling impacts on a host of metallo-enzymes as well as key modulating genes that in sum, result in significant anti-inflammatory, anti-oxidant and anti-apoptotic effects as well as vasodilation and anti-adhesion of cells to the endothelium resulting in preservation of vascular flow. CO may also have a role as an anti-polymerization HbS agent. In addition, considerable scientific data in the non-SCD literature provide evidence for a beneficial impact of CO on cerebrovascular complications, suggesting that in SCD, CO could potentially limit these highly problematic neurologic outcomes. Research is needed and hopefully forthcoming, to carefully elucidate the safety and benefits of this potential therapy across the age spectrum of patients impacted by the host of pathophysiological complications of this devastating disease.
机译:镰状细胞疾病(SCD)是一种痛苦的终身血红蛋白病,作为血红蛋白(HB)β-珠蛋白基因中的畸形点突变。这种疾病对生活质量和死亡率产生了重大影响,因此需要大量的医疗,以减少血管闭塞危机,这是疾病的病理生理学。气态分子可能发挥生物功能的概念已在一百年内众所周知。虽然二氧化碳(CO)在SCD中进行了50多年,但最近作为一种能够调节一系列生理和治疗过程的强大的细胞保护生物反应改性剂,其在低浓度下施加在各种组织模型中的关键生理功能炎症和损伤。 CO由血红素氧合酶的血红素代谢生理生理,并在血液中测量。已经产生了具有CO的大量临床前和临床数据,这为CO作为许多病理条件中的潜在治疗提供了令人信服的支持。包括SCD的CO的治疗机制的数据已经由包含多种SCD小鼠模型的多种体外和临床前研究产生的。这些数据显示CO具有对一系列金属酶的关键信号影响以及总和的键调节基因,导致显着的抗炎,抗氧化剂和抗凋亡效应以及血管舒张和抗粘连细胞到内皮细胞导致保存血管流动。 CO也可以具有抗聚合HBs剂的作用。此外,非SCD文献中的相当大的科学数据提供了CO对脑血管并发症的有益影响的证据,这表明在SCD中,CO可能会限制这些高度有问题的神经系统结果。需要研究并希望即将到来,仔细阐明这种潜在治疗的安全性和益处,这些潜在治疗的患者受到这种破坏性疾病的病理生理并发症的宿主的年龄谱。

著录项

  • 来源
    《American Journal of Hematology》 |2017年第6期|共14页
  • 作者单位

    Hillhurst Biopharmaceut Inc 2029 Verdugo Blvd 125 Montrose CA 91020 USA;

    Univ Minnesota 420 Delaware St SE MMC 480 Minneapolis MN 55455 USA;

    Harvard Med Sch Beth Israel Deaconess Med Ctr 3 Blackfan Circle Ctr Life Sci 630 Boston MA;

    Childrens Hosp Los Angeles 4650 Sunset Blvd MS 54 Los Angeles CA 90027 USA;

    Childrens Hosp Los Angeles 4650 Sunset Blvd MS 54 Los Angeles CA 90027 USA;

    Hillhurst Biopharmaceut Inc 2029 Verdugo Blvd 125 Montrose CA 91020 USA;

    Hillhurst Biopharmaceut Inc 2029 Verdugo Blvd 125 Montrose CA 91020 USA;

    Univ Minnesota 420 Delaware St SE MMC 480 Minneapolis MN 55455 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 血液及淋巴系疾病;
  • 关键词

  • 入库时间 2022-08-20 01:45:29

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号